[Subacute cutaneous lupus erythematosus and cancer: two cases and literature review]

Ann Dermatol Venereol. 2011 May;138(5):409-17. doi: 10.1016/j.annder.2011.02.015. Epub 2011 Apr 17.
[Article in French]

Abstract

Background: Subacute cutaneous lupus erythematosus is an uncommon dermatosis characterised by a non-scarring, annular photo-distributed dermatosis associated with anti-Ro/SSA antibodies. It is remarkable as a paraneoplastic syndrome (12 cases in the literature). We report two cases of subacute cutaneous lupus erythematosus occurring in patients treated for metastatic breast adenocarcinoma.

Case reports: Case 1: a 72-year-old woman with breast carcinoma relapsing after surgery, chemotherapy, hormone therapy, and without treatment for 6 months, was admitted for an acute erythematous slightly squamous and photo-distributed eruption. On clinical examination, she was found to be presenting polyadenopathy and pleural effusion. Case 2: a 46-year-old woman with a history of breast carcinoma was admitted for an erythematopapular, annular and photo-distributed eruption occurring after a second breast cancer relapse and five months after initiation of docetaxel. A new line of chemotherapy initially resulted in regression of the lesions, and progression of the breast cancer was associated with cutaneous relapse.

Discussion: The diagnosis of subacute cutaneous lupus erythematosus was supported in our two patients by the presence of an annular photo-distributed eruption associated with positive testing for anti-Ro/SSA antibodies. Occurrence of the eruption in both cases with relapse of the neoplasia and its improvement after oncological treatment reinforced the diagnosis of paraneoplastic syndrome in one case, and the use of chemotherapy known to trigger lupus could have suggested a diagnosis of drug-induced subacute cutaneous lupus erythematosus. Thus, the association between lupus and cancer is relevant.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adenocarcinoma / complications*
  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / radiotherapy
  • Adenocarcinoma / surgery
  • Aged
  • Antibodies, Antinuclear / blood
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Autoantigens / immunology
  • Bevacizumab
  • Breast Neoplasms / complications*
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / radiotherapy
  • Breast Neoplasms / surgery
  • Combined Modality Therapy
  • Cyclophosphamide / administration & dosage
  • Docetaxel
  • Epirubicin / administration & dosage
  • Female
  • Fluorouracil / administration & dosage
  • Humans
  • Lupus Erythematosus, Cutaneous / chemically induced
  • Lupus Erythematosus, Cutaneous / diagnosis
  • Lupus Erythematosus, Cutaneous / etiology*
  • Lupus Erythematosus, Cutaneous / immunology
  • Mastectomy / methods
  • Middle Aged
  • Paclitaxel / administration & dosage
  • Paraneoplastic Syndromes / chemically induced
  • Paraneoplastic Syndromes / diagnosis
  • Paraneoplastic Syndromes / etiology*
  • Paraneoplastic Syndromes / immunology
  • Ribonucleoproteins / immunology
  • Salvage Therapy
  • Tamoxifen / therapeutic use
  • Taxoids / administration & dosage
  • Taxoids / adverse effects
  • Trastuzumab

Substances

  • Antibodies, Antinuclear
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Hormonal
  • Autoantigens
  • Ribonucleoproteins
  • SS-A antibodies
  • SS-A antigen
  • Taxoids
  • Tamoxifen
  • Docetaxel
  • Bevacizumab
  • Epirubicin
  • Cyclophosphamide
  • Trastuzumab
  • Paclitaxel
  • Fluorouracil

Supplementary concepts

  • FEC protocol